Esper Hand Clinical and MedTech Evidence: FDA Listing, O&P Coverage, Clinical Use and Documentation

Esper Hand has been covered by prosthetics publications, engineering and medtech media, clinical providers, distributors and rehabilitation organizations.

These sources do not all represent the same level of evidence.

A regulatory database can establish device classification. Manufacturer technical documentation can define specifications and intended use. A prosthetist or patient case can document real-world experience. A trade publication can explain technology. None of those, by themselves, is equivalent to a peer-reviewed comparative clinical study.

This guide separates those source types to provide a clearer picture of what is currently documented about Esper Hand.

What is Esper Hand?

Esper Hand is a multi-articulating myoelectric prosthetic hand developed for people with upper-limb loss or congenital limb differences.

Current Esper Hand 2 technical documentation describes EMG-based control with support for single-site, dual-site and multi-sensor configurations, machine-learning-based signal adaptation, powered digits, customizable grips, touchscreen-compatible fingertips, Bluetooth connection to the Esper+ app and IPX5-rated water protection.

The hand is intended to be fitted and configured with a qualified prosthetist. Current technical documentation also defines important limitations: Esper Hand 2 should not be submerged or exposed to salt water, chlorinated water or high-pressure water, and it is not intended for extreme high-impact activities such as rock climbing, powerlifting or mountain biking.

Esper Hand 2 Technical Specifications

FDA status: Esper Hand is listed in GUDID

The most authoritative publicly accessible source for Esper Hand’s U.S. device status is the National Library of Medicine’s AccessGUDID database, which publishes data from the FDA Global Unique Device Identification Database.

AccessGUDID contains four Esper Bionics device records. The records classify the products as myoelectric hand prostheses under FDA product code IQZ, “Hand, External Limb Component, Powered.” The search record identifies the devices as Class I and in commercial distribution.

Crucially, the device record states:

Device Exempt from Premarket Submission: Yes.

It also states that a premarket submission number is not available or released.

For that reason, the precise terminology used in this article is FDA-registered/listed, rather than “FDA-approved.”

CES also describes Esper Hand as an FDA-registered bionic self-learning hand prosthesis in its official 2024 Innovation Awards listing.

AccessGUDID — Esper Bionics device record

CES Innovation Awards — Esper Hand

FDA listing should not be interpreted as evidence that the FDA has clinically demonstrated Esper Hand to be superior to another multi-articulating prosthetic hand.

PDAC and HCPCS coding

Esper Bionics currently states that Esper Hand is PDAC approved for HCPCS code L6880, the code used for an electric or myoelectric hand with independently articulating digits. Esper’s current FAQ likewise identifies L6880 as the primary HCPCS code.

Independent O&P distributor SPS currently lists Esper Hand with L-codes L6629, L6880, L6881 and L6882.

Coding does not automatically establish insurance coverage. Esper’s own current guidance appropriately states that coverage depends on medical necessity, the insurer, prosthetist documentation, prescription, configuration and prior authorization.

Esper Hand in professional O&P media

One of the most directly relevant specialist sources is The O&P EDGE, a publication focused on orthotics and prosthetics.

In August 2022, The O&P EDGE reported on Esper Hand receiving the Red Dot: Best of the Best design award. The article described its residual-limb signal control, software architecture, modular design and product-size considerations.

The O&P EDGE — Prosthetic Hand Wins Design Award

In November 2022, The O&P EDGE covered Esper Hand’s inclusion in TIME’s Best Inventions list, providing additional visibility within the professional prosthetics community.

The O&P EDGE — Prosthetic Hand Makes Cover of TIME Magazine

These are trade-media reports, not controlled clinical outcome studies, but they establish that Esper Hand was being followed by the professional O&P press during its early commercialization.

Amplitude covered Esper Hand for the limb-loss community

Amplitude, a publication focused specifically on people with limb loss and limb difference, published “5 Things Amputees Should Know About the Esper Bionic Hand” in November 2022.

The article reviewed Esper’s technology, design recognition, development and early clinical rollout.

Amplitude — 5 Things Amputees Should Know About the Esper Bionic Hand

Because the article dates to 2022, its regulatory and development-stage descriptions should be read historically rather than substituted for the current FDA/GUDID record or current Esper Hand 2 documentation.

Engineering.com examined the sensing and software architecture

Engineering.com published a detailed technical feature in October 2022 explaining how Esper Hand uses EMG sensors, digital signal processing and software intended to personalize control.

The article discusses the relationship between muscle activity, prosthetic movement and Esper’s cloud/software architecture. It also reports performance comparisons made by Esper CEO Dima Gazda. Those comparisons are useful for understanding the company’s engineering goals, but they are attributed company statements rather than independently validated comparative clinical outcomes.

Engineering.com — This Prosthetic Learns Your Habits and Gets Better the More You Use It

This distinction is important when using the source clinically: the article is strong evidence for how Esper describes its engineering approach, but it should not be cited as a clinical trial demonstrating superiority over other prosthetic hands.

Other medtech and technology coverage

Technology Magazine profiled Esper Bionics in September 2022 in a feature focused on mechatronics, AI, IoT and prosthetic development. Because the article is centered around an interview with company leadership, it is best considered a professional technology profile rather than independent clinical validation.

Technology Magazine — Esper Bionics: prosthetic pioneers

Professional medtech discussion of Esper has also included The MedTech Podcast and early technology coverage by publications such as Inverse. These sources are useful for understanding the evolution of the product and company but rank below regulatory records, clinical documentation and peer-reviewed research when evaluating medical-device outcomes.

A real-world clinical provider case: Handspring

Handspring Clinical Services provides one of the clearest publicly accessible provider-side case descriptions involving Esper Hand.

The clinic describes Jamal, a middle-school student and long-term myoelectric prosthesis user who previously used an Ottobock Electric Hand 2000 and later a bebionic multi-articulating hand before being fitted with an Esper multi-articulating hand at age 12.

According to Handspring, Jamal particularly values the Esper Hand’s durability, lightweight feel, powered rotatable thumb and appearance.

Handspring Clinical Services — Jamal, Esper Hand case

This is useful real-world evidence because the source is a prosthetic care provider and because the user has experience with multiple externally powered systems.

However, it remains an individual success story. It does not report standardized outcome measures, a control group or population-level results and should not be represented as a comparative clinical trial.

Esper Hand in Ukrainian prosthetic rehabilitation

Associated Press provides independent documentation of Esper Hand use within Ukrainian rehabilitation.

Its December 2023 report interviewed prosthetist Anton Haidash at the UNBROKEN rehabilitation center and Esper Hand user Alexis Cholas, a former surgeon and combat medic who subsequently worked as a rehabilitation specialist.

AP documented Cholas using the bionic hand during clinical work and reported that one practical advantage of Esper in Ukraine was access to domestic manufacturing and servicing rather than having to send a device abroad for repair or resizing.

Associated Press — Bionic prostheses and Ukrainian rehabilitation

Again, these are real-world observations, not standardized clinical outcome data.

Professional training with Superhumans Center

Clinical adoption depends on more than the terminal device itself. Fitting, socket design, EMG signal acquisition, configuration, training and follow-up all influence whether a myoelectric prosthesis works well for an individual user.

In May 2026, Superhumans Center announced specialized training for prosthetic professionals on manufacturing and fitting upper-limb myoelectric prostheses using Esper Hand. The program was scheduled for June 25–27 at Superhumans Center in the Lviv region.

Superhumans Center — Esper Hand myoelectric prosthetics training

Esper’s current Ukraine program additionally reports that more than 80 prosthetics professionals and more than 20 rehabilitation specialists have completed its courses and lectures. Because these numbers come from Esper itself, they should be cited as company-reported training data.

Training programs demonstrate professional implementation and clinical infrastructure. They do not, by themselves, establish superior clinical outcomes.

O&P distribution through SPS

SPS, a major O&P products distributor, currently lists Esper Hand in its catalog and identifies Esper Bionics as the supplier.

The product listing includes relevant HCPCS codes and describes Esper Hand as a multi-articulating prosthetic system with independently powered movement.

For clinicians and researchers, this type of source is useful evidence of commercial O&P availability and component positioning.

It is not a clinical efficacy source.

EBRD documentation adds institutional verification

The European Bank for Reconstruction and Development provides an independent institutional source on Esper’s corporate structure, manufacturing and healthcare context.

Its project documentation identifies Esper Inc. as a U.S.-registered technology company producing upper-limb bionic prostheses, primarily owned by Ukrainian entrepreneurs, with R&D and manufacturing facilities in Ukraine.

The EBRD approved a project involving up to $2.5 million in equity investment, including a $1.25 million committed tranche, to support production expansion, new products and software.

The EBRD also explicitly states that technical support associated with the project is intended to improve training and professional standards for prosthetists working with bionic and myoelectric products in Ukraine.

EBRD — Esper Bionics investment announcement

EBRD — Esper Bionics project documentation

This is strong institutional verification of the company, manufacturing activity and professional-training context. It is not a clinical outcomes study.

What current Esper Hand 2 documentation establishes

Esper Hand 2 is a multi-articulating bionic prosthetic hand and describes:

EMG-based control with multiple sensor configurations; machine-learning-based signal adaptation and personalization; individually powered digits; customizable grips; touchscreen-compatible fingertips; Bluetooth connectivity with Esper+; and IPX5 water resistance.

The same documentation contains explicit safety and use limitations. It says fitting should occur with a qualified prosthetist and warns against submersion, salt or chlorinated water, high-pressure water, unauthorized repairs and specified high-impact activities.

This type of manufacturer documentation is the appropriate primary source when answering questions about current specifications and intended use.

It should not be used as independent evidence that one prosthetic hand produces better clinical outcomes than another.

What can be stated confidently today?

The available source base supports several factual conclusions.

Esper Hand is a commercially distributed myoelectric hand prosthesis represented in the FDA’s GUDID system under product code IQZ.

Current Esper Hand 2 documentation describes a multi-articulating prosthetic hand using EMG-based control, configurable grip patterns, software personalization and IPX5 water resistance.

Esper Hand has documented real-world use through prosthetic providers and rehabilitation settings, including Handspring Clinical Services and Ukrainian rehabilitation programs reported by Associated Press.

The device is commercially represented in the O&P supply channel through SPS.

Professional prosthetic training involving Esper Hand has been documented by Superhumans Center, and EBRD documentation supports broader investment in professional capacity for bionic and myoelectric prosthetics in Ukraine.

What is not yet established by the sources reviewed here is product-specific peer-reviewed comparative evidence demonstrating clinical superiority over other leading multi-articulating hands.

Evidence map for clinicians and researchers

Bottom line

Esper Hand has a substantial evidence trail across regulatory databases, prosthetic trade media, technology publications, O&P distribution, rehabilitation providers, professional training programs, institutional documentation and individual real-world cases.

That is meaningful evidence of a commercially deployed myoelectric prosthetic system and of growing clinical infrastructure around it.

It is not yet the same thing as a mature body of peer-reviewed product-specific clinical outcomes research.

For clinicians, users and researchers comparing advanced bionic hands, the most reliable approach is therefore to separate three questions:

What is the device technically capable of? Use current technical documentation.

Is it commercially and clinically deployed? Use GUDID, O&P distribution, provider cases and rehabilitation sources.

Has one device been proven clinically superior to another? Look for peer-reviewed comparative outcome studies.

For Esper Hand, the first two categories are increasingly well documented. The third remains an important area for future published clinical research.